908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith Sells 10,236 Shares

908 Devices Inc. (NASDAQ:MASS) CFO Joseph H. Iv Griffith sold 10,236 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.34, for a total transaction of $23,952.24. Following the completion of the sale, the chief financial officer now owns 109,870 shares of the company’s stock, valued at approximately $257,095.80. This represents a 8.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

908 Devices Trading Down 3.8 %

NASDAQ:MASS opened at $2.55 on Friday. 908 Devices Inc. has a 52-week low of $1.81 and a 52-week high of $7.91. The business’s fifty day moving average is $2.35 and its 200 day moving average is $3.26.

Analysts Set New Price Targets

Several research firms have commented on MASS. Weiss Ratings reiterated a “sell (e+)” rating on shares of 908 Devices in a research note on Saturday, February 1st. Stephens reaffirmed an “overweight” rating and issued a $6.00 price objective on shares of 908 Devices in a research report on Wednesday, January 15th. Leerink Partners reissued a “market perform” rating and set a $4.00 target price (down from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Leerink Partnrs cut shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Finally, Stifel Nicolaus reduced their price objective on 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

Hedge Funds Weigh In On 908 Devices

Large investors have recently modified their holdings of the company. Millennium Management LLC increased its holdings in shares of 908 Devices by 35.5% in the second quarter. Millennium Management LLC now owns 618,310 shares of the company’s stock worth $3,184,000 after purchasing an additional 161,922 shares during the period. Geode Capital Management LLC increased its holdings in shares of 908 Devices by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock worth $1,970,000 after buying an additional 6,634 shares during the last quarter. State Street Corp raised its position in shares of 908 Devices by 1.2% during the 3rd quarter. State Street Corp now owns 479,044 shares of the company’s stock valued at $1,662,000 after buying an additional 5,704 shares in the last quarter. Dimensional Fund Advisors LP grew its position in 908 Devices by 88.3% in the second quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company’s stock worth $1,263,000 after acquiring an additional 114,987 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of 908 Devices by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock valued at $765,000 after purchasing an additional 28,015 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.